Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of anti-infection biotech Inhibitex (Nasdaq: INHX) seem immune to today's general market malaise, jumping as much as 12.9% in pretty heavy trading.

So what: A Reuters report written in German reminded investors this morning that Swiss pharma giant Roche just might be interested in buying the company for about $2 billion. The gains quickly subsided when everyone realized that Reuters was simply reporting on rumors from earlier this week, which so far haven't led to any actual buyout offers.

Now what: And so the rumor mill reinforces itself like an echo chamber. That said, an Inhibitex buyout isn't out of the question as larger rival Pharmasset (Nasdaq: VRUS) is getting swallowed by Gilead Sciences (Nasdaq: GILD) in an $11 billion blockbuster deal. Antivirals are a hot property, and Inhibitex has its fair share of good-looking drug candidates in the pipeline.

Interested in more info about Inhibitex? Click here to add it to My Watchlist.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis -- even one of our own -- helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.